Ian Millss bilde

Ian Mills

  • E-postian.mills@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. PLoS Medicine.
  • Vis forfatter(e) (2022). Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases. 755-761.
  • Vis forfatter(e) (2022). Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer. European Urology Open Science. 68-75.
  • Vis forfatter(e) (2022). Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer. Nature Communications. 12 sider.
  • Vis forfatter(e) (2022). A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Molecular Cancer. 22 sider.
  • Vis forfatter(e) (2021). Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nature Communications.
  • Vis forfatter(e) (2021). Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications.
  • Vis forfatter(e) (2021). Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases.
  • Vis forfatter(e) (2021). Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. Scientific Reports.
  • Vis forfatter(e) (2021). CaMKK2 facilitates Golgi-associated vesicle trafficking to sustain cancer cell proliferation. Cell Death & Disease. 1-12.
  • Vis forfatter(e) (2020). Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells. Communications Biology. 11 sider.
  • Vis forfatter(e) (2020). Methodology for the at-home collection of urine samples for prostate cancer detection. BioTechniques. 65-73.
  • Vis forfatter(e) (2020). Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9. Molecular Cancer Research. 1512-1521.
  • Vis forfatter(e) (2020). Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. Scientific Reports. 1-10.
  • Vis forfatter(e) (2020). Identification and Validation of Leucine-rich alpha-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science. 51-61.
  • Vis forfatter(e) (2020). African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer.
  • Vis forfatter(e) (2019). The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells. Molecular Cancer Research. 2154-2168.
  • Vis forfatter(e) (2019). Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer. Scientific Reports. 1-10.
  • Vis forfatter(e) (2019). IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications. 1-12.
  • Vis forfatter(e) (2019). High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. Theranostics. 2183-2197.
  • Vis forfatter(e) (2019). Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Scientific Reports. 1-11.
  • Vis forfatter(e) (2019). CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. Neoplasia. 713-720.
  • Vis forfatter(e) (2019). A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU International. 609-620.
  • Vis forfatter(e) (2018). Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Annals of Oncology. 215-222.
  • Vis forfatter(e) (2018). Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. The BMJ. 1-7.
  • Vis forfatter(e) (2018). Identification of shared genetic variants between schizophrenia and lung cancer. Scientific Reports. 1-8.
  • Vis forfatter(e) (2018). Genetic factors influencing prostate cancer risk in Norwegian men. The Prostate. 186-192.
  • Vis forfatter(e) (2017). c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks. EBioMedicine. 83-93.
  • Vis forfatter(e) (2017). The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports.
  • Vis forfatter(e) (2017). Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications.
  • Vis forfatter(e) (2017). Molecular subgroup of primary prostate cancer presenting with metastatic biology. European Urology. 509-518.
  • Vis forfatter(e) (2017). Lipid degradation promotes prostate cancer cell survival. OncoTarget. 38264-38275.
  • Vis forfatter(e) (2017). Dual transcriptome of the immediate neutrophil and Candida albicans interplay. BMC Genomics. 696.
  • Vis forfatter(e) (2017). Correction to: Dual transcriptome of the immediate neutrophil and Candida albicans interplay. BMC Genomics. 863.
  • Vis forfatter(e) (2017). Bromodomain-containing proteins in prostate cancer. Molecular and Cellular Endocrinology. 31-40.
  • Vis forfatter(e) (2017). Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics. 1-11.
  • Vis forfatter(e) (2017). Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer. Cell reports. 2045-2059.
  • Vis forfatter(e) (2016). Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2. Biochemical and Biophysical Research Communications - BBRC. 102-107.
  • Vis forfatter(e) (2016). The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. European Urology. 214-218.
  • Vis forfatter(e) (2016). Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. PLoS Medicine.
  • Vis forfatter(e) (2016). Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing. Methods in molecular biology. 119-137.
  • Vis forfatter(e) (2016). Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. OncoTarget. 12464-12476.
  • Vis forfatter(e) (2016). HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. OncoTarget. 74734-74746.
  • Vis forfatter(e) (2016). Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine. 103-116.
  • Vis forfatter(e) (2016). Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics. 387-397.
  • Vis forfatter(e) (2016). Data for the co-expression and purification of human recombinant CaMKK2 in complex with calmodulin in Escherichia coli. Data in Brief. 733-740.
  • Vis forfatter(e) (2016). Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute.
  • Vis forfatter(e) (2016). Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells. Epigenetics & Chromatin.
  • Vis forfatter(e) (2016). Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 1655-1668.
  • Vis forfatter(e) (2015). UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene. 3744-3750.
  • Vis forfatter(e) (2015). The androgen receptor controls expression of the cancerassociated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. OncoTarget. 34358-34374.
  • Vis forfatter(e) (2015). Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLOS ONE.
  • Vis forfatter(e) (2015). Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Molecular Cancer Research. 620-635.
  • Vis forfatter(e) (2015). Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. OncoTarget. 12587-12602.
  • Vis forfatter(e) (2015). Macroautophagic cargo sequestration assays. Methods. 25-36.
  • Vis forfatter(e) (2015). Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 1133-1144.
  • Vis forfatter(e) (2015). Glucocorticoid receptor and Klf4 co-regulate anti-inflammatory genes in keratinocytes. Molecular and Cellular Endocrinology. 281-289.
  • Vis forfatter(e) (2015). Genetic sharing with cardiovascular disease risk factors and diabetes reveals novel bone mineral density loci. PLOS ONE.
  • Vis forfatter(e) (2015). Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. EMBO Molecular Medicine. 788-801.
  • Vis forfatter(e) (2015). Autophagic bulk sequestration of cytosolic cargo is independent of LC3, but requires GABARAPs. Experimental Cell Research. 21-38.
  • Vis forfatter(e) (2015). Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLOS ONE.
  • Vis forfatter(e) (2015). A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate. The Analyst. 8109-8117.
  • Vis forfatter(e) (2014). The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches. PLOS ONE. 32 sider.
  • Vis forfatter(e) (2014). The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Research (NAR). 6256-6269.
  • Vis forfatter(e) (2014). Studying N-linked glycosylation of receptor tyrosine kinases. Methods in molecular biology. 103-109.
  • Vis forfatter(e) (2014). Shared common variants in prostate cancer and blood lipids. International Journal of Epidemiology. 1205-1214.
  • Vis forfatter(e) (2014). Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO Journal. 1365-1382.
  • Vis forfatter(e) (2014). Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Medical Genomics. 513.
  • Vis forfatter(e) (2014). HES6 drives a critical AR transcriptional programme to induce castration‐resistant prostate cancer through activation of an E2F1‐mediated cell cycle network. EMBO Molecular Medicine. 651-661.
  • Vis forfatter(e) (2014). Endosomal signalling and oncogenesis. Methods in Enzymology. 179-200.
  • Vis forfatter(e) (2014). Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocrine-Related Cancer. T57-T66.
  • Vis forfatter(e) (2013). The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer. European Urology. 702-708.
  • Vis forfatter(e) (2013). The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man. Cancer Cell. 35-47.
  • Vis forfatter(e) (2013). O-GlcNAc Transferase Integrates Metabolic Pathways to Regulate the Stability of c-MYC in Human Prostate Cancer Cells. Cancer Research.
  • Vis forfatter(e) (2013). N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor. PLOS ONE. 10 sider.
  • Vis forfatter(e) (2013). Modulation of intracellular calcium homeostasis blocks autophagosome formation. Autophagy. 1475-1490.
  • Vis forfatter(e) (2013). Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins. European Urology. 347-353.
  • Vis forfatter(e) (2013). Disseminated tumor cells and their prognostic significance in non-metastatic prostate cancer patients. International Journal of Cancer. 149-155.
  • Vis forfatter(e) (2012). PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21. American Journal of Pathology. 2097-2107.
  • Vis forfatter(e) (2012). Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements. Neoplasia. 600-+.
  • Vis forfatter(e) (2012). Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 11252-11257.
  • Vis forfatter(e) (2012). ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. Journal of Clinical Investigation. 4621-4634.
  • Vis forfatter(e) (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal. 2719-2733.
  • Vis forfatter(e) (2011). Principles for the post-GWAS functional characterization of cancer risk loci. Nature Genetics. 513-518.
  • Vis forfatter(e) (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal. 3019-3027.
  • Vis forfatter(e) (2010). Taking Risks with Translational Research. Science Translational Medicine. 4 sider.
Vitenskapelig foredrag
  • Vis forfatter(e) (2013). Molecular and Structural Characterization of Sjögren syndrome/scleroderma autoantigen 1, a new binding partner of Tankyrase regulated by the oncogene c-Myc.
  • Vis forfatter(e) (2016). Maintaining a Healthy Balance: Targeting TERT to Stem Benign Prostatic Hyperplasia. European Urology. 555-556.
  • Vis forfatter(e) (2015). Molecular subtyping of prostate cancer: a partnership model. European Urology. 568-569.
  • Vis forfatter(e) (2011). Bridging the gaps: From risk loci via non-coding RNAs to gene networks and prostate cancer phenotypes. Cell Cycle. 4204-4204.
Short communication
  • Vis forfatter(e) (2016). Pleiotropic analysis of lung cancer and blood triglycerides. Journal of the National Cancer Institute. 1-4.
  • Vis forfatter(e) (2012). Androgen Receptor Affects Glycosylation Pathways to Alter Growth Factor Receptor Signalling. European Journal of Cancer. S72-S73.
  • Vis forfatter(e) (2017). O-GlcNAc transferase inhibition in breast cancer cells .
  • Vis forfatter(e) (2016). Inhibition of O-GlcNAc transferase in breast cancer cells .
  • Vis forfatter(e) (2016). Inhibition of O-GlcNAc transferase in breast cancer cells.
  • Vis forfatter(e) (2014). Metabolic and transcriptomic profiling of cancer cells treated with O-linked N-acetylglucosamine transferase inhibitor (STO45849).
  • Vis forfatter(e) (2022). Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer (Nature Communications, (2022), 13, 1, (466), 10.1038/s41467-022-28069-2). Nature Communications.
  • Vis forfatter(e) (2020). Correction to: Human-Based Exposure Levels of Perfluoroalkyl Acids May Induce Harmful Effects to Health by Disrupting Major Components of Androgen Receptor Signalling In Vitro (Exposure and Health, (2020), 12, 3, (527-538), 10.1007/s12403-019-00318-8). Exposure and Health. 929.
  • Vis forfatter(e) (2017). Erratum: Dual transcriptome of the immediate neutrophil and Candida albicans interplay. [BMC Genomics. 18, (2017) (696)] DOI: 10.1186/s12864-017-4097-4. BMC Genomics. 1-21.
  • Vis forfatter(e) (2017). Corrigendum to "Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study" [EBioMedicine 2 (9) (2015) 1133-1144] (S2352396415300712) (10.1016/j.ebiom.2015.07.017)). EBioMedicine. 238-238.
  • Vis forfatter(e) (2015). Correction: Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLOS ONE.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2021). Vascular normalisation as the stepping stone into tumour microenvironment transformation. British Journal of Cancer. 324-336.
  • Vis forfatter(e) (2021). The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects. Frontiers in Oncology.
  • Vis forfatter(e) (2017). The importance of DNA methylation in prostate cancer development. Journal of Steroid Biochemistry and Molecular Biology. 1-15.
  • Vis forfatter(e) (2016). The role of glycans in the development and progression of prostate cancer. Nature reviews. Urology. 324-333.
  • Vis forfatter(e) (2016). CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions. Nucleic Acids Research (NAR). 10588-10602.
  • Vis forfatter(e) (2014). Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nature Reviews Cancer. 187-198.
  • Vis forfatter(e) (2014). HOXB13, RFX6 and prostate cancer risk. Nature Genetics. 94-95.
  • Vis forfatter(e) (2012). Nuclear translocation and functions of growth factor receptors. Seminars in Cell and Developmental Biology. 165-171.
  • Vis forfatter(e) (2012). Chromatin binding by the androgen receptor in prostate cancer. Molecular and Cellular Endocrinology. 44-51.

Se fullstendig oversikt over publikasjoner i CRIStin.